[Basic knowledge of drug pain therapy in the palliative situation]
- PMID: 40562057
- DOI: 10.1055/a-2544-4239
[Basic knowledge of drug pain therapy in the palliative situation]
Abstract
This review provides an overview of the basic knowledge of drug pain therapy in the palliative situation. Pain is one of the main symptoms in 60 to 90% of cancer patients. Pain also develops with neurological and other diseases that occur in end-of-life situations. To address this symptom, a holistic strategy is required that encompasses all physical, psychological, social, and spiritual aspects of the multi-dimensional pain experience ("total pain" concept).Drug treatment for cancer pain has been based on a stepwise approach for many years, starting with non-opioid analgesics, followed by moderate and strong opioids. In contrast, today's pain management is determined more by the actual intensity of this aversive event.The pain assessment should be tailored to identify a nociceptive vs. a neuropathic pain component that needs to be challenged by the most appropriate drug therapies. Non-opioid analgesics are ideal substances for relieving nociceptive pain. Antidepressants and anticonvulsants reduce the intensity of new neuropathic pain. Opioids are suitable for all types of pain, but are restricted to a second-line choice. Among all opioids are Tilidine and Tramadol prodrugs, which only relieve pain after activation in the liver. Drug-drug interactions may also block this activation. Rapid release opioids should be used for break-through cancer pain. Transdermal opioid applications are recommended in case of swallowing disorders, but usually not to initiate pain control. An opioid change can be performed if side effects such as hallucinations for the selected opioid are more pronounced than the pain reduction.
Thieme. All rights reserved.
Conflict of interest statement
SW, JS, VPP, SH, IN: Keine Interessenkonflikte. AL: Vorträge für Grünenthal, Research agreement mit Roche. FE: Beratertätigkeit oder Vorträge für TEVA, Berlin Chemie, Menarini Group, Grünenthal. RR: Beratertätigkeit oder Vorträge für AOP Orphan, bionorica ethics, Grünenthal, Pfizer, Tilray Deutschland. Konsortialführer des G-BA Innovationsfonds-Projektes APVEL (Förderkennzeichen: 01VSF16007). Ko-Sprecher der Ärztinnen und Ärzte der Deutschen Gesellschaft für Palliativmedizin und Neuropalliativen Arbeitsgemeinschaft. RR und AL (Ko-Sprecherin) erhalten Forschungsförderung durch das BMBF-Projekt Bio2Treat (Förderkennzeichen: 13GW0334B).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
